Aldosterone synergizes with peripheral inflammation to induce brain IL-1β expression and depressive-like effects

Cytokine

Volumn 60, Issue 3, 2012, Pages 749-754

  Bay Richter, Cecilie ^a   Hallberg, Ludvig ^a   Ventorp, Filip ^a   Janelidze, Shorena ^a   Brundin, Lena ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Aldosterone; Depression; Forced swim test; IL 1 ; LPS

Indexed keywords

ALDOSTERONE; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 1; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; GENE EXPRESSION; HORMONE ACTION; HYPERALDOSTERONISM; INFLAMMATION; MALE; NONHUMAN; OSMOTIC MINIPUMP; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYMPTOM;

ALDOSTERONE; ANIMALS; BEHAVIOR, ANIMAL; CYTOKINES; DEPRESSION; DEPRESSIVE DISORDER; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; PREFRONTAL CORTEX; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER;

RATTUS;

EID: 84867990840     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.08.016     Document Type: Article

References (36)

1. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003, 289:3095-3105.
2. Brundtland G.H. From the World Health Organization. Mental health: new understanding, new hope. JAMA 2001, 286:2391.
3. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur Psychiatry 2002, 17(Suppl 3):294-299.
4. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
5. Boron W.F., Boulpaep E.L. Medical physiology: a cellular and molecular approach 2003, W.B. Saunders, Philadelphia (PA). 1st ed.
6. Emanuele E., Geroldi D., Minoretti P., Coen E., Politi P. Increased plasma aldosterone in patients with clinical depression. Arch Med Res 2005, 36:544-548.
7. Sonino N., Tomba E., Genesia M.L., Bertello C., Mulatero P., Veglio F., et al. Psychological assessment of primary aldosteronism: a controlled study. J Clin Endocrinol Metab 2011, 96:878-883.
8. Hallberg L., Westrin A., Isaksson A., Janelidze S., Traskman-Bendz L., Brundin L. Decreased aldosterone in the plasma of suicide attempters with major depressive disorder. Psychiatry Res 2011, 187:135-139.
9. Hishimoto A., Shirakawa O., Nishiguchi N., Hashimoto T., Yanagi M., Nushida H., et al. Association between a functional polymorphism in the renin-angiotensin system and completed suicide. J Neural Transm 2006, 113:1915-1920.
10. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
11. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
12. Wichers M., Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002, 5:375-388.
13. Luther J.M., Gainer J.V., Murphey L.J., Yu C., Vaughan D.E., Morrow J.D., et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006, 48:1050-1057.
14. Francis J., Beltz T., Johnson A.K., Felder R.B. Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-alpha in normal rats. Am J Physiol Regul Integr Comp Physiol 2003, 285:1402-1409.
15. Cheng Z.J., Vapaatalo H., Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005, 11:194-205.
16. Marchesi C., Paradis P., Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008, 29:367-374.
17. Sanchez-Lemus E., Murakami Y., Larrayoz-Roldan I.M., Moughamian A.J., Pavel J., Nishioku T., et al. Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland. Endocrinology 2008, 149:5177-5188.
18. Steckelings U.M., Rompe F., Kaschina E., Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 2009, 23:693-703.
19. Kubzansky L.D., Adler G.K. Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev 2010, 34:80-86.
20. Scalco A.Z., Scalco M.Z., Azul J.B., Lotufo Neto F. Hypertension and depression. Clinics (Sao Paulo) 2005, 60:241-250.
21. Hlavacova N., Wes P.D., Ondrejcakova M., Flynn M.E., Poundstone P.K., Babic S., et al. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol 2012, 15:247-265.
22. Bay-Richter C., Janelidze S., Hallberg L., Brundin L. Changes in behaviour and cytokine expression upon a peripheral immune challenge. Behav Brain Res 2011, 222:193-199.
23. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003, 463:3-33.
24. Cryan J.F., Lucki I. Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. J Pharmacol Exp Ther 2000, 295:1120-1126.
25. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
26. Tonelli L.H., Holmes A., Postolache T.T. Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology 2008, 33:1038-1048.
27. Bonefeld B.E., Elfving B., Wegener G. Reference genes for normalization: a study of rat brain tissue. Synapse 2008, 62:302-309.
28. Ando H., Zhou J., Macova M., Imboden H., Saavedra J.M. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004, 35:1726-1731.
29. Zhou J., Ando H., Macova M., Dou J., Saavedra J.M. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 2005, 25:878-886.
30. Miyoshi M., Nagata K., Imoto T., Goto O., Ishida A., Watanabe T. ANG II is involved in the LPS-induced production of proinflammatory cytokines in dehydrated rats. Am J Physiol Regul Integr Comp Physiol 2003, 284:1092-1097.
31. Leroy V., De Seigneux S., Agassiz V., Hasler U., Rafestin-Oblin M.E., Vinciguerra M., et al. Aldosterone activates NF-kappaB in the collecting duct. J Am Soc Nephrol 2009, 20:131-144.
32. Queisser N., Oteiza P.I., Stopper H., Oli R.G., Schupp N. Aldosterone induces oxidative stress, oxidative DNA damage and NF-kappaB-activation in kidney tubule cells. Mol Carcinog 2011, 50:123-135.
33. Yu Y., Kang Y.M., Zhang Z.H., Wei S.G., Chu Y., Weiss R.M., et al. Increased cyclooxygenase-2 expression in hypothalamic paraventricular nucleus in rats with heart failure: role of nuclear factor kappaB. Hypertension 2007, 49:511-518.
34. Fogari R., Preti P., Zoppi A., Rinaldi A., Fogari E., Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007, 30:111-117.
35. Douma S., Petidis K., Doumas M., Papaefthimiou P., Triantafyllou A., Kartali N., et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008, 371:1921-1926.
36. Nasr S.J., Crayton J.W., Agarwal B., Wendt B., Kora R. Lower frequency of antidepressant use in patients on renin-angiotensin-aldosterone system modifying medications. Cell Mol Neurobiol 2011, 31:615-618.